Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

40,991 stories, page 414 of 684

Advanced search

🌍Jul 28discoverynews.google.comTier 2 · Trade media

RA Capital launches Oak Hill Bio onto the Nasdaq via SPAC

Fierce BiotechOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

FDA Peptide Vote Signals Potential Shift in Compounding and Beauty Regulation

BeautyMatterOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

FDA Approves Simtriyo | PharmExec

Pharmaceutical ExecutiveOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Why is Biohaven Pharmaceutical stock gaining today?

Investing.comOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

First patient enrolled in Phase 3 trial of mocertatug rezetecan for platinum-resistant ovarian cancer

Bioengineer.orgOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

First patient enrolled in GOG-3132/BEHOLD-Ovarian01 phase 3 study evaluating Mocertatug Rezetecan, a novel B7-H4–targeted ADC, in platinum-resistant ovarian cancer

EurekAlert!Original source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Promising biotech stocks with analyst upside targets of up to 242%

Investing.comOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Phase 3 clinical trial enrolls first platinum-resistant ovarian cancer patient

News-MedicalOriginal source

🌍Jul 28Industryeikontx.comTier 1 · Company source

Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer

Eikon TherapeuticsOriginal source

🇪🇺Jul 28Researchcordis.europa.euTier 2 · Direct publisher

CORDIS project: Pain relief in palliative care of cancer using home-based neuromodulation and predictive biomarkers

CORDISOriginal source

🇪🇺Jul 28Researchcordis.europa.euTier 2 · Direct publisher

CORDIS project: SoluTions foR mItiGatinG climate-induced hEalth tReaths

CORDISOriginal source

🇪🇺Jul 28Researchcordis.europa.euTier 2 · Direct publisher

CORDIS project: Integrated Services for Infectious Disease Outbreak Research

CORDISOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

FDA Moves to Eliminate Two Food Dye Authorizations

MyChesCoOriginal source

🇪🇺Jul 28Researchcordis.europa.euTier 2 · Direct publisher

CORDIS project: Co-creation methodology for biotechnology trust-building measures for improved innovation uptake in the bio-based innovation system

CORDISOriginal source

🇪🇺Jul 28Researchcordis.europa.euTier 2 · Direct publisher

CORDIS project: PREVENTING AND DELAYING THE DEVELOPMENT OF DIABETES IN AFRICA: A RANDOMISED PLACEBO -CONTROLLED DOUBLE-BLIND PHASE III TRIAL OF METFORMIN IN HIV-INFECTED PERSONS WITH PRE-DIABETES

CORDISOriginal source

🇪🇺Jul 28Researchcordis.europa.euTier 2 · Direct publisher

CORDIS project: Sustainable eThics Reviews of digital heAlth Technology dEsiGn In sub saharan afriCa

CORDISOriginal source

🇪🇺Jul 28Researchcordis.europa.euTier 2 · Direct publisher

CORDIS project: Diagnostic HER2DX-guided treatment for patients with early-stage HER2-positive breast cancer

CORDISOriginal source

🇪🇺Jul 28Researchcordis.europa.euTier 2 · Direct publisher

CORDIS project: Right-time Adaptive Particle Therapy Of canceR - Personalisation through anatomical plus biological adaptation

CORDISOriginal source

🇪🇺Jul 28Researchcordis.europa.euTier 2 · Direct publisher

CORDIS project: Oxygen Optimization Therapy through BCPAP for management of childhood pneumonia in general hospitals of LMICs

CORDISOriginal source

🇪🇺Jul 28Researchcordis.europa.euTier 2 · Direct publisher

CORDIS project: Building a Decolonized Ethics and Governance Framework for Just and Trustworthy AI in Healthcare

CORDISOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

A new ADHD drug just got FDA approval. Here's what makes it different.

KTENOriginal source

🌍Jul 28discoverynews.google.comTier 2 · Trade media

FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’

Fierce PharmaOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Amgen Halts Key Phase 3 Rocatinlimab Study, Resetting Expectations in Dermatology

TipRanksOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Arrowhead completes enrollment in Phase 3 YOSEMITE trial

TipRanksOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Winners And Losers Of Q1: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Branded Pharmaceuticals Stocks

Yahoo! Finance CanadaOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?

Zacks Investment ResearchOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Investors Turn Bullish on This Biotech Stock Heading Into Catalyst

TheStreet ProOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Why the Medicines Hospitals Need Most Are Least Profitable

Pharmaceutical CommerceOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Legend Biotech Shares Fall After CEO Huang Resigns

marketscreener.comOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Branford-based biotech Quantum-Si at risk of Nasdaq delisting, again

Hartford Business JournalOriginal source

🌍Jul 28discoverynews.google.comTier 3 · Aggregated media

Taiwan biotech looks outward in next phase of growth

BioWorld NewsOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

AstraZeneca Pressure Puts Krystal Biotech, TG Therapeutics And Gilead Stocks In Focus

simplywall.stOriginal source

🌍Jul 27discoverynews.google.comTier 2 · Trade media

FDA scientists question Capricor data; Legend CEO steps down

BioPharma DiveOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

FDA Panel Backs Two Peptides For Compounding, Rejects One

U.S. News & World ReportOriginal source

🌍Jul 27discoverynews.google.comTier 2 · Trade media

Apnimed aspires for up to $160M IPO as sleep apnea launch nears

Fierce BiotechOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Cspc Pharmaceutical Says Nmpa Accepts New Drug Application For Sirolimus For Injection (Albumin-Bound)

TradingViewOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Capricor Provides Update on Deramiocel for DMD Ahead of FDA Meeting

Intellectia AIOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

4th Circuit could hear NC abortion drug case in October

Carolina JournalOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

FDA Panel Backs Two Peptides For Compounding, Rejects One

HealthDayOriginal source

🇺🇰Jul 27Industrygsk.comTier 1 · Company source

ViiV Healthcareâ€™s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV

GSK NewsOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

AstraZeneca’s HSCT-TMA drug misses main endpoint

EMJOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Mid-Year Check-In: Where Is Patient Access Headed?

Pharmaceutical CommerceOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Raymond James cuts Legend Biotech stock price target on CEO departure

Investing.comOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Active Biotech comments on first dose in updated myelofibrosis study

BiostockOriginal source

🌍Jul 27discoverynews.google.comTier 2 · Trade media

InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis test

Fierce BiotechOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

FBRX Stock Extends Rally As Barclays Lifts Biotech Hopes

StocksToTradeOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Earnings Preview: Ono Pharmaceutical Co. (OPHLF) Q1 Earnings Expected to Decline

Yahoo FinanceOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Why is Legend Biotech stock sliding today?

Investing.comOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Pakistan, China Sign $850 Million Deals to Boost Pharmaceutical Cooperation

The Diplomat – Asia-PacificOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Cambridge biotech taps external executive to lead after Elevidys controversy

The Business JournalsOriginal source

🇺🇰Jul 27Regulatorygov.ukTier 1 · Regulatory source

Medicine supply disruption statistics, UK: data to June 2026

Twice-yearly official statistics on medicine supply issue and discontinuation notifications reported...

UK Department of Health and Social CareOriginal source

🌍Jul 27discoverynews.google.comTier 2 · Trade media

From confidence to capital: Positioning biotech for the next growth cycle

BioPharma DiveOriginal source

🌍Jul 27discoverynews.google.comTier 2 · Trade media

Legend Biotech CEO abruptly steps down without permanent replacement

Fierce PharmaOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Can Takeda Pharmaceutical (TSE:4502) Trade At A Discount On New Phase 3 Psoriasis Data?

simplywall.stOriginal source

🌍Jul 27discoverynews.google.comTier 2 · Trade media

Pharmalittle: We're reading about a U.S. peptide panel's votes, Amgen scuffling with the FDA, and more

STATOriginal source

🇺🇰Jul 27Devicespresspart.comTier 1 · Company source

Customer Satisfaction Survey 2026

H&T PresspartOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Crystalys Therapeutics Raises $130 Million Series B, Strengthening Fortress Biotech's Dotinurad Stake

citybizOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

FDA Approves First-in-Class Centanafadine for Treatment of ADHD

Drug TopicsOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Vaccines Are Safe. A Worrisome Portion Of Our Generic Drugs Are Not

ForbesOriginal source

🌍Jul 27discoverynews.google.comTier 2 · Trade media

Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug

STATOriginal source